0001654954-21-001276.txt : 20210208 0001654954-21-001276.hdr.sgml : 20210208 20210208120741 ACCESSION NUMBER: 0001654954-21-001276 CONFORMED SUBMISSION TYPE: 8-A12B PUBLIC DOCUMENT COUNT: 1 FILED AS OF DATE: 20210208 DATE AS OF CHANGE: 20210208 FILER: COMPANY DATA: COMPANY CONFORMED NAME: GT Biopharma, Inc. CENTRAL INDEX KEY: 0000109657 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 941620407 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-A12B SEC ACT: 1934 Act SEC FILE NUMBER: 001-40023 FILM NUMBER: 21600222 BUSINESS ADDRESS: STREET 1: 9350 WILSHIRE BLVD. STREET 2: SUITE 203 CITY: BEVERLY HILLS STATE: CA ZIP: 90212 BUSINESS PHONE: (800) 304-9888 MAIL ADDRESS: STREET 1: 9350 WILSHIRE BLVD. STREET 2: SUITE 203 CITY: BEVERLY HILLS STATE: CA ZIP: 90212 FORMER COMPANY: FORMER CONFORMED NAME: OXIS INTERNATIONAL INC DATE OF NAME CHANGE: 19940916 FORMER COMPANY: FORMER CONFORMED NAME: DDI PHARMACEUTICALS INC DATE OF NAME CHANGE: 19920703 FORMER COMPANY: FORMER CONFORMED NAME: DIAGNOSTIC DATA INC /DE/ DATE OF NAME CHANGE: 19850312 8-A12B 1 gtbp_8k.htm 8-A12B gtbp_8k
 

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
 
FORM 8-A
 
FOR REGISTRATION OF CERTAIN CLASSES OF SECURITIES
PURSUANT TO SECTION 12(b) OR 12(g) OF
THE SECURITIES EXCHANGE ACT OF 1934
 
GT BIOPHARMA, INC.
(Exact name of registrant as specified in its charter)
 
 
Delaware
(State or other jurisdiction of
incorporation or organization)
94-1620407
(I.R.S. Employer
Identification Number)
 
9350 Wilshire Blvd. Suite 203
Beverly Hills, CA 90212
 (Address of principal executive offices and zip code)
 
(800) 304-9888
(Registrant’s telephone number, including area code)
 
N/A
(Former name, former address and former fiscal year, if changed since last report)
 
Securities registered pursuant to Section 12(b) of the Act:
 
Title of Each Class
 
Trading Symbol
 
Name of exchange on which registered
Common Stock
 
GTBP
 
The Nasdaq Stock Market LLC
 
 
If this form relates to the registration of a class of securities pursuant to Section 12(b) of the Exchange Act and is effective pursuant to General Instruction A.(c) or (e), check the following box.  ☒
 
If this form relates to the registration of a class of securities pursuant to Section 12(g) of the Exchange Act and is effective pursuant to General Instruction A(d) or (e), check the following box.  ☐
 
If this form relates to the registration of a class of securities concurrently with a Regulation A offering, check the following box.  ☐
 
Securities Act registration statement or Regulation A offering statement file number to which this form relates: 333-251311
 
Securities to be registered pursuant to Section 12(g) of the Act: None.
 

 
 
 
Item 1. Description of the Registrant’s Securities to Be Registered.
 
The securities to be registered hereby of GT Biopharma, Inc. (the “Registrant”) are common stock, par value $0.001 per share, of the Registrant. The description of the common stock set forth under the heading “Description of Securities” in the prospectus forming part of the Registrant’s Registration Statement on Form S-1 (File No. 333-251311), originally filed with the Securities and Exchange Commission on December 11, 2020, as thereafter amended and supplemented from time to time (the “Registration Statement”), is incorporated by reference herein. Any form of prospectus or prospectus supplement to the Registration Statement that includes such descriptions and that is subsequently filed is hereby also incorporated by reference herein.
 
Item 2. Exhibits.
 
Pursuant to the Instructions as to Exhibits for Form 8-A, no exhibits are required to be filed, because no other securities of the Registrant are registered on the Nasdaq Stock Market LLC, and the securities registered hereby are not being registered pursuant to Section 12(g) of the Securities Exchange Act of 1934, as amended.
 
 
 
 
SIGNATURES
 
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.
 
 
GT Biopharma, Inc.
 
 
 
 
 
Dated: February 8, 2021
By:  
/s/ Michael Handelman  
 
 
 
Michael Handelman
 
 
 
Chief Financial Officer